<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01542138</url>
  </required_header>
  <id_info>
    <org_study_id>NIADESAH</org_study_id>
    <nct_id>NCT01542138</nct_id>
  </id_info>
  <brief_title>Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation</brief_title>
  <official_title>A Double Blind, Randomized Clinical Trial of 4% Niacinamide Versus 0.05% Desonide for the Treatment of Axillar Hyperpigmentation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universidad Autonoma de San Luis Potosí</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad Autonoma de San Luis Potosí</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Axillary hyperpigmentation is a frequent consultation in dark skin populations although its
      exact prevalency is unknown. Currently, there are not studies about physiopathology and
      treatment for this entity. The objective is to evaluate the depigmenting effect of topical 4%
      niacinamide versus 0.05% desonide in axillary hyperpigmentation.

      At least 30 axillas with hyperpigmentation in individuals of phototype III-V, aged 18-50
      years are going to be randomly assigned to receive niacinamide, desonide or placebo daily. No
      hygienic habits will not be modified. Volunteers will be evaluated at baseline and for 9
      weeks, by means of histological, histochemical and immunohistochemistry analysis, as well as
      Transepidermal Water Loss (TEWL), colorimetry, clinically and by photography control.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Axillary hyperpigmentation is frequent in dark skin population, is possible a type of
      postinflammatory hyperpigmentation present in phototypes IV to VI. Previous reports have
      described increased intensity of Masson-Fontana, anti-tyrosinase and/or anti-TRP1 staining,
      indicative of melanocyte stimulation and increased melanin production, but the exact
      mechanism is unknown. The hair plucking, the rubbing of clothes on skin and physical
      stimulation from washing and drying the underarm are factors implicated. The objective of our
      study is evaluate the depigmenting effect of topical niacinamide versus desonide in axillary
      hyperpigmentation through the histochemistry and immunohistochemistry staining.

      The study population will include at least 30 axillas with hyperpigmentation in a population
      with phototype III-V and aged 18-50 years old. Informed consent will be obtained from the
      patients, under approval by the local ethical committee (Institutional Review Board). The
      patients are going to be randomly assigned to receive 4% niacinamide, 0.05% desonide or
      placebo daily once at night. None hygienic habit is going to be modified. Volunteers will be
      evaluated at baseline and 9 weeks later, with histochemical and immunohistochemical analysis
      (biopsies), colorimetric value axis L*, a*, b* (Chromameter CR-300, Minolta, Osaka, Japan),
      Transepidermal Water Loss (TEWL) by means of an evaporimeter (Dermalab, Cortex Technology,
      Denmark), clinical assessment and photography control.

      Statistical analysis was performed using t student, the level of significance was set at 5%.
      And clinical evaluation will be analysed by means of chi square test.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Actual">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pigmentation</measure>
    <time_frame>9 weeks</time_frame>
    <description>Quantification of melanin content in histologic sections by Fontana-Masson stain</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Inflammation</measure>
    <time_frame>9 weeks</time_frame>
    <description>Quantification of inflammatory infiltrate in skin biopsies by histologic lymphocites infiltrate and immunohistochemistry stain anti-CD1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trauma</measure>
    <time_frame>9 weeks</time_frame>
    <description>To detect trauma we measure damage in Membrane Basal by anti-collagen IV immunohistochemistry stain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in transepidermal water loss in hyperpigmented lesion</measure>
    <time_frame>9 weeks</time_frame>
    <description>Quantification of water loss measured by a evaporimeter in grams per squared meter per hour. Is an indirect measure of inflammation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Depigmentation Improvement</measure>
    <time_frame>9 weeks</time_frame>
    <description>Clinical improvement is assessed by means of digital photographic registration (frontal, right, and left views). Two independent observers clinically graded the global improvement as poor (0-25%), mild (26-50%), good (51-75%), and excellent (&gt;75%).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Hyperpigmentation</condition>
  <arm_group>
    <arm_group_label>Niacinamide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4% niacinamide cream that will be randomly applied on axillar hyperpigmentation once-a-day for 9 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desonide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once-a-day application of 0.05% desonide cream on axillar hyperpigmentation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Humectant placebo cream</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desonide</intervention_name>
    <description>Once-a-day applying on axillar hyperpigmentation for 9 weeks</description>
    <arm_group_label>Desonide</arm_group_label>
    <other_name>0.05% Desowen cream, Galderma, France.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Niacinamide</intervention_name>
    <description>Once-a-day applying on axillar hyperpigmentation for 9 weeks</description>
    <arm_group_label>Niacinamide</arm_group_label>
    <other_name>Nicotinamide, nicomide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Humectant placebo cream</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>vanicream, cetaphil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women over 18 years old

          -  Healthy

          -  Clinical diagnosis of axillar hyperpigmentation

        Exclusion Criteria:

          -  Pregnancy or lactation

          -  Obesity

          -  Endocrinological diseases

          -  Mental diseases

          -  Treatment for axillar hyperpigmentation in the last 2 months
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bertha Torres-Alvarez, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dermatology Department. Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;, San Luis Potosi, México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gabryela N Larraga-Piñones, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermatology Department. Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;. San Luis Potosi, México</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan P Castanedo-Cázares, MD</last_name>
    <role>Study Director</role>
    <affiliation>Dermatology Department. Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;. San Luis Potosi, México</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dermatology Department. Hospital Central &quot;Dr. Ignacio Morones Prieto&quot;</name>
      <address>
        <city>San Luis Potosi</city>
        <zip>78210</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <reference>
    <citation>Navarrete-Solís J, Castanedo-Cázares JP, Torres-Álvarez B, Oros-Ovalle C, Fuentes-Ahumada C, González FJ, Martínez-Ramírez JD, Moncada B. A Double-Blind, Randomized Clinical Trial of Niacinamide 4% versus Hydroquinone 4% in the Treatment of Melasma. Dermatol Res Pract. 2011;2011:379173. doi: 10.1155/2011/379173. Epub 2011 Jul 21.</citation>
    <PMID>21822427</PMID>
  </reference>
  <reference>
    <citation>Torres-Álvarez B, Mesa-Garza IG, Castanedo-Cázares JP, Fuentes-Ahumada C, Oros-Ovalle C, Navarrete-Solis J, Moncada B. Histochemical and immunohistochemical study in melasma: evidence of damage in the basal membrane. Am J Dermatopathol. 2011 May;33(3):291-5. doi: 10.1097/DAD.0b013e3181ef2d45.</citation>
    <PMID>21317614</PMID>
  </reference>
  <verification_date>November 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2012</study_first_submitted>
  <study_first_submitted_qc>February 24, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2012</study_first_posted>
  <last_update_submitted>November 27, 2012</last_update_submitted>
  <last_update_submitted_qc>November 27, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universidad Autonoma de San Luis Potosí</investigator_affiliation>
    <investigator_full_name>Juan Pablo Castanedo Cazares</investigator_full_name>
    <investigator_title>Dermatology research director</investigator_title>
  </responsible_party>
  <keyword>Inflammatory hyperpigmentation, axillar pigmentation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperpigmentation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
    <mesh_term>Desonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

